Acute myeloid leukemia (AML) and related neoplasms

Acute myeloid leukemia (AML) and related neoplasms are hematological disorders characterized by the rapid growth of abnormal myeloid cells in the bone marrow and blood. At Invivoscribe, we provide cutting-edge diagnostic products and services for the characterization of these myeloid disorders. Our comprehensive solutions aim to improve subject outcomes by offering accurate and reliable testing options.

MyAML^® Gene Panel Assay

Identifying genetic mutations in genes associated with AML helps predict prognosis and aids in treatment decision-making. Our CLIA-validated MyAML^® assay can detect pathogenic mutations in 194 genes related to acute myeloid leukemia. It follows the guidelines of respected institutions such as NCCN and ELN. The MyAML^® Gene Panel Assay is a highly sensitive test that can spot somatic mutations as low as 1% allelic frequency. This assay utilizes next-generation sequencing (NGS) technology, allowing for simultaneous analysis of multiple genes involved in myeloid disorders. It provides a comprehensive genetic profile and helps identify potential therapeutic targets for patient management.

FLT3 Testing

In AML patients, mutations in the FLT3 (fms-related tyrosine kinase 3) gene are common and often indicate a higher risk of relapse and a less favorable prognosis. Invivoscribe offers a range of globally standardized testing solutions to detect FLT3 mutations. Our precise tests provide critical data to clinicians, enabling them to personalize treatment plans and monitor a patient’s response to therapy.

MyMRD^® Gene Panel Assay

Accurate minimal residual disease (MRD) monitoring is crucial for managing myeloid malignancies like AML. It helps relapse and assess the treatment response of patients with these diseases.

The MyMRD^® Gene Panel assay is a precise tool that detects genetic variants driving these diseases. It uses deep sequencing and targets 23 genes to identify low-level mutations linked to disease development, prognosis, and recurrence. This assay enables sensitive and early residual disease detection, facilitating timely intervention and potentially improving patient outcomes.

Reach Out to Us

Invivoscribe is dedicated to providing state-of-the-art products and services to aid in diagnosing and monitoring myeloid disorders, including AML and related neoplasms. We are committed to improving patient outcomes and advancing precision diagnostics. Connect with us to learn more about our solutions and how they can benefit your patients.